Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Table 5 Echocardiographic and NT-proBNP measurements of Patients Evaluated After METT^a (28 weeks)

Measurement	Group	N	Mean	95% Confidence Interval for Mean	P ^b
NT-proBNP²	All Patients	59	47.3^c	(36.3, 61.6)^c	< 0.01
LV End-Diastolic Posterior Wall Thickness Z-score	All Patients	78	−0.29	(− 0.60, 0.02)	0.06
	Female	30	− 0.57	(−1.04, − 0.09)	0.02
	Male	48	−0.10	(− 0.50, 0.30)	0.63
End-Diastolic Septal Thickness Z-score	All Patients	70	−0.84	(−1.2, − 0.48)	< 0.01
	Female	27	−1.20	(−1.76, −0.64)	< 0.01
	Male	43	−0.60	(−1.06, − 0.15)	0.01
LV Fractional Shortening Z-score	All Patients	81	−0.19	(−0.54, 0.17)	0.30
	Female	32	−0.46	(−1.02, 0.10)	0.10
	Male	49	0.00	(−0.46, 0.47)	0.99
LV Mass Z-score	All Patients	74	−0.74	(−1.06, − 0.42)	< 0.01
	Female	29	−1.23	(−1.71, −0.75)	< 0.01
	Male	45	−0.39	(−0.80, 0.01)	0.06

^aMETT minimal expected treatment time
^bIn the Z-score columns, a Z-score of 0 represents the average value for a healthy child of the same age. Each P-value for the Z-score measurements is from the two-sided hypothesis test with the null hypothesis H₀: the population mean for the Z-scores is 0. (A Z-score of 0 represents the average value for a healthy child of the same age.) The P-value for NT-proBNP is from the two-sided hypothesis test with null hypothesis H₀: the population geometric mean is 100
^cNT-proBNP is a raw score. Analysis for the NT-proBNP was done using a natural log transformation to stabilize the variance. The back-transformed NT-proBNP numbers are presented here for ease of interpretability. Due to the back transformations, these represent geometric means

ISSN: 2057-3804